About Diagnovus
Diagnovus is a company based in Nashville (United States) founded in 2011 was acquired by Aegis Science in January 2015. Diagnovus operates in a competitive market with competitors including InDex Pharmaceuticals, C3J Therapeutics, Genedrive, Combinati and Qantgene, among others.
- Headquarter Nashville, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Aegis Science
& 1 more
-
Employee Count
Not available
-
Acquired by
Aegis Science
(Jan 06, 2015)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Diagnovus
Investors in Diagnovus
Diagnovus has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Aegis Science and TriStar Health Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Drug testing and clinical laboratory services are provided.
|
Locked | Locked | Locked |
Investor details for Diagnovus
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Diagnovus
Investment portfolio details for Diagnovus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Diagnovus
Detailed financials for Diagnovus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Diagnovus Comparisons
Peer comparison for Diagnovus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Diagnovus
Diagnovus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as InDex Pharmaceuticals, C3J Therapeutics, Genedrive, Combinati and Qantgene, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
DNA-based immunomodulatory drugs for ulcerative colitis are developed.
|
|
| Locked | Locked | Locked |
Pathogen-specific antimicrobials are developed for microbial dysbiosis diseases.
|
|
| Locked | Locked | Locked |
Provider of point of care molecular diagnostics platform for genotyping and sequence analysis
|
|
| Locked | Locked | Locked |
Integrated digital PCR platform with microfluidic consumables is developed.
|
|
| Locked | Locked | Locked |
Cancer screening blood tests are offered for early disease detection.
|
|
| Locked | Locked | Locked |
PCR-based Human and Animal testing for vector-borne diseases
|
Detailed competitors of Diagnovus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Diagnovus
Complete news archive for Diagnovus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Diagnovus
Diagnovus was founded in 2011.
Diagnovus is headquartered in Nashville, United States. It is registered at Nashville, Tennessee, United States.
Diagnovus was founded in 2011 and based in Nashville, United States. Molecular diagnostics for rare diseases were developed and offered by the company in the healthcare sector. Operations focused on three market products: a PCR-based test assessing Barretts esophageal cancer risk, a gene expression test for eosinophilic esophagitis, and a pharmacogenetic test using buccal swabs. The company was acquired by Aegis Sciences.
Diagnovus's top competitors include C3J Therapeutics, InDex Pharmaceuticals and Genedrive.
Diagnovus has 2 investors. Key investors include Aegis Science, and TriStar Health Partners.